Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 249-259

  Hersh, Carrie M ^a   Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

alemtuzumab; autoimmune adverse events; CD52; monoclonal antibody; relapsing remitting multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; CORTICOSTEROID; ANTIRHEUMATIC AGENT; BETA INTERFERON; CD52 ANTIGEN; GLYCOPROTEIN; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN ATROPHY; DRUG CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEMORY CELL; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; T LYMPHOCYTE; ATROPHY; AUTOIMMUNE DISEASES; B LYMPHOCYTE; BRAIN; CHEMISTRY; DISABILITY; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFECTION; LYMPHOCYTE DEPLETION; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE BLIND PROCEDURE; STATISTICS AND NUMERICAL DATA; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIRHEUMATIC AGENTS; ATROPHY; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; BRAIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISABILITY EVALUATION; FEMALE; GLYCOPROTEINS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; INFECTION; INTERFERON-BETA; LYMPHOCYTE DEPLETION; MALE; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SINGLE-BLIND METHOD; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84899569012     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.7     Document Type: Article

References (47)

1. Compston A, Coles A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
2. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005).
3. Prineas J, Kwon E, Cho E et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646-657 (2001).
4. Rice GPA, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis. Mechanisms and rationale. Neurology 64, 1336-1342 (2005).
5. Polman CH, O'Connor PW, Hardova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
6. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923 (2006).
7. Kappos L, Radue E-W, O'Connor P et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
8. Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
9. O'Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293-1303 (2011).
10. Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomized, double-blind, placebo-controlled Phase IIb study. Lancet 372, 1463-1472 (2008).
11. Fox R, Miller D, Phillips JT et al. Placebo-controlled Phase 3 study of oral bg-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087-1097 (2012).
12. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3, 137-143 (2001).
13. Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Structure of the CAMPATH-1 antigen. Biochem. J. 293, 633-640 (1993).
14. Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332-3342 (2005).
15. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Investig.119, 2052-2061 (2009).
16. Thompson SA, Jones JL, Cox AL, Compston DAS, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 30, 99-105 (2010).
17. Cheetham GM, Hale G, Waldmann H, Bloomer AC. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol. 284, 85-99 (1998).
18. Kirchhoff C, Krull N, Pera I, Ivell R. A major mRNA of the human epididymal principal cells, HE5, encodes the leukocyte differentiation CDw52 antigen peptide backbone. Mol. Reprod. Dev. 34, 8-15 (1993).
19. Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128, 260-270 (2009).
20. Wing mg, Moreau T, Greenwood J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Investig. 98, 2819-2826 (1996).
21. Moreau T, Coles A, Wing mg, Isaacs J, Waldmann H, Compston A. Tranisent increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119, 225-237 (1996).
22. Zhang X, Tao Y, Chopra M et al. Differential reconstitution of t cell subsets following immunodepleting treatment with alemtuzumab (anti-cd52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J. Immunol. 191, 5867-5874 (2013).
23. Jones JL, Anderson JM, Phuah CL et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133, 2232-2247 (2010).
24. Coles AJ, Twyman CL, Arnold DL et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: A randomised controlled Phase 3 trial. Lancet 380(9856), 1829-1839 (2012).
25. Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled Phase 3 trial. Lancet 380(9856), 1819-1828 (2012).
26. Ali R, Nicholas RSJ, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 73, 625-650 (2013).
27. Le Page E, Leray E, Taurin G et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry 79, 52-56 (2008).
28. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3, 261-267 (2001).
29. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: Assay development and validation. J. Immuno. Methods 260, 285-302 (2002).
30. Sørensen PS, Arnold DL, Cohen JA et al. Immunogenicity of Alemtuzumab Treatment in relapsing-remitting multiple sclerosis (RRMS) patients in the CARE-MS II study. Neurology 80(Abstract 1), P07.101 (2013).
31. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
32. Cobbold SP, Jayasuriy A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312, 548-551 (1984).
33. Dyer MJ, Hale G, Hayhoe HG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73, 1431-1439 (1989).
34. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 332, 323-327 (1988).
35. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99, 3554-3561 (2002).
36. Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298-301 (1994).
37. Coles AJ, Wing MG, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691-1695 (1999).
38. Coles AJ, Wing mg, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46, 296-304 (1999).
39. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J. Neurol. 253, 98-108 (2006).
40. Coles A, Group CS. Alemtuzumab vs. interferon beta-1a in early MS. N. Engl. J. Med. 359, 1786-1801 (2008).
41. Coles AJ, Fox E, Vladic A et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78, 1069-1078 (2012).
42. Freedman MS, Arnold DL, Cohen JA et al. Efficacy of Alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II): Subgroup analysis by previous DMT use. Neurology 80(Abstract 1), P07.111 (2013).
43. Khan O, Arnold DL, Cohen JA et al. Anti-IFNB-1a antibody status was not a factor influencing efficacy of Alemtuzumab vs. IFNB-1a in relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II). Neurology 80(Abstract 1), P07.125 (2013).
44. Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2, 60-63 (2013).
45. Wynn D Arnold DL Cohen JA et al. Detection, incidence and management of glomerulonephritis in the alemtuzumab clinical development programme. Presented at: ECTRIMS Copenhagen, Denmark, 2-5 October 2013.
46. Coles A. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 10, 29-33 (2013).
47. McCarthy CL, Tuohy R, Compston A, Kumararatne D, Coles A, Jones J. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 81, 872-876 (2013).